Total Payments
$65,492
2024 Payments
$23,966
Companies
17
Transactions
52
Medicare Patients
9,589
Medicare Billing
$1.8M
Payment Breakdown by Category
Consulting$52,750 (80.5%)
Other$5,247 (8.0%)
Research$4,100 (6.3%)
Food & Beverage$2,773 (4.2%)
Travel$621.98 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $52,750 | 13 | 80.5% |
| Honoraria | $4,800 | 1 | 7.3% |
| Unspecified | $4,100 | 1 | 6.3% |
| Food and Beverage | $2,773 | 30 | 4.2% |
| Travel and Lodging | $621.98 | 2 | 0.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $447.20 | 5 | 0.7% |
Payments by Type
General
$61,392
51 transactions
Research
$4,100
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma Global Development | $47,700 | 11 | $0 (2024) |
| Merck Sharp & Dohme LLC | $7,483 | 7 | $0 (2022) |
| Alimera Sciences, Inc. | $5,377 | 5 | $0 (2022) |
| Genentech USA, Inc. | $2,115 | 1 | $0 (2024) |
| NotalVision | $689.34 | 9 | $0 (2019) |
| Notal Vision, Inc. | $326.32 | 2 | $0 (2024) |
| Vertex Pharmaceuticals Incorporated | $325.00 | 1 | $0 (2021) |
| Genentech, Inc. | $316.13 | 4 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $232.84 | 2 | $0 (2023) |
| Apellis Pharmaceuticals, Inc. | $189.85 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,966 | 7 | Astellas Pharma Global Development ($21,800) |
| 2023 | $26,467 | 12 | Astellas Pharma Global Development ($25,900) |
| 2022 | $13,087 | 15 | Merck Sharp & Dohme LLC ($7,483) |
| 2021 | $757.38 | 4 | Vertex Pharmaceuticals Incorporated ($325.00) |
| 2020 | $105.08 | 1 | Bausch & Lomb, a division of Bausch Health US, LLC ($105.08) |
| 2019 | $236.34 | 2 | NotalVision ($127.64) |
| 2018 | $288.16 | 5 | NotalVision ($288.16) |
| 2017 | $585.58 | 6 | NotalVision ($273.54) |
All Payment Transactions
52 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/20/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Consulting Fee | Cash or cash equivalent | $2,115.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 03/21/2024 | Notal Vision, Inc. | Foresee Home (Device) | Food and Beverage | In-kind items and services | $51.32 | General |
| Category: Ophthalmology | ||||||
| 01/06/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $5,500.00 | General |
| Category: Ophthalmology | ||||||
| 01/06/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $5,500.00 | General |
| Category: Ophthalmology | ||||||
| 01/06/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| Category: Ophthalmology | ||||||
| 01/06/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| Category: Ophthalmology | ||||||
| 01/06/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: Ophthalmology | ||||||
| 12/29/2023 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $5,500.00 | General |
| Category: Ophthalmology | ||||||
| 12/01/2023 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| Category: Ophthalmology | ||||||
| 11/08/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $124.14 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/01/2023 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| Category: Ophthalmology | ||||||
| 10/01/2023 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $5,500.00 | General |
| Category: Ophthalmology | ||||||
| 09/13/2023 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $93.11 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 09/08/2023 | Astellas Pharma Global Development | Izervay (Drug) | — | Cash or cash equivalent | $4,100.00 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atropy Secondary to Age-Related Macular Degeneration • Category: Ophthalmology | ||||||
| 09/01/2023 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: Ophthalmology | ||||||
| 06/07/2023 | Genentech, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $136.36 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/07/2023 | Genentech, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/11/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $98.07 | General |
| Category: Ophthalmology | ||||||
| 02/22/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $91.78 | General |
| Category: Ophthalmology | ||||||
| 12/29/2022 | Bausch & Lomb Americas Inc. | XIPERE (Drug), RETISERT | Food and Beverage | In-kind items and services | $34.19 | General |
| Category: Ophthalmology | ||||||
| 10/31/2022 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Food and Beverage | Cash or cash equivalent | $88.25 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/01/2022 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Honoraria | Cash or cash equivalent | $4,800.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/03/2022 | Genentech, Inc. | SUSVIMO (Drug), VABYSMO | Food and Beverage | In-kind items and services | $40.48 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/06/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 06/06/2022 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atropy Secondary to Age-Related Macular Degeneration | Astellas Pharma Global Development | $4,100 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 2,597 | 6,087 | $2.8M | $332,577 |
| 2022 | 13 | 2,563 | 6,001 | $2.7M | $312,803 |
| 2021 | 14 | 2,958 | 5,857 | $2.7M | $548,701 |
| 2020 | 12 | 1,471 | 3,560 | $2.0M | $603,597 |
Total Patients
9,589
Total Services
21,505
Medicare Billing
$1.8M
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 67028 | Injection of drug into eye | Facility | 2023 | 301 | 1,583 | $1.7M | $118,345 | 6.9% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 700 | 1,262 | $367,242 | $110,060 | 30.0% |
| 92134 | Imaging of retina | Office | 2023 | 509 | 1,755 | $301,860 | $49,133 | 16.3% |
| 92250 | Photography of the retina | Office | 2023 | 488 | 725 | $137,025 | $18,592 | 13.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 108 | 116 | $56,608 | $10,849 | 19.2% |
| 92240 | Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye | Office | 2023 | 36 | 41 | $24,190 | $5,791 | 23.9% |
| 67221 | Destruction of vascular growth between retina and sclera by photodynamic therapy | Facility | 2023 | 25 | 29 | $36,192 | $4,509 | 12.5% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 245 | 360 | $22,680 | $3,982 | 17.6% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Facility | 2023 | 12 | 19 | $49,362 | $3,617 | 7.3% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 31 | 31 | $10,850 | $3,110 | 28.7% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 30 | 40 | $14,840 | $1,360 | 9.2% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 27 | 28 | $9,212 | $1,193 | 12.9% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 53 | 60 | $5,940 | $1,045 | 17.6% |
| 67515 | Injection of drug or substance into membrane covering eyeball | Facility | 2023 | 32 | 38 | $9,240 | $991.04 | 10.7% |
| 67028 | Injection of drug into eye | Facility | 2022 | 310 | 1,631 | $1.7M | $117,695 | 6.8% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 709 | 1,198 | $348,677 | $103,601 | 29.7% |
| 92134 | Imaging of retina | Office | 2022 | 527 | 1,727 | $296,985 | $47,230 | 15.9% |
| 92250 | Photography of the retina | Office | 2022 | 565 | 844 | $159,516 | $21,742 | 13.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 71 | 76 | $37,088 | $6,709 | 18.1% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2022 | 226 | 353 | $22,239 | $3,941 | 17.7% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 28 | 28 | $9,800 | $3,073 | 31.4% |
| 92240 | Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye | Office | 2022 | 18 | 21 | $12,390 | $3,072 | 24.8% |
| 67221 | Destruction of vascular growth between retina and sclera by photodynamic therapy | Facility | 2022 | 15 | 15 | $18,720 | $2,285 | 12.2% |
| 92083 | Exam of visual field with extended testing | Office | 2022 | 36 | 37 | $12,173 | $1,632 | 13.4% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2022 | 14 | 24 | $8,904 | $840.21 | 9.4% |
About Dr. Priyatham Mettu, M.D
Dr. Priyatham Mettu, M.D is a Ophthalmology healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/20/2008. The National Provider Identifier (NPI) number assigned to this provider is 1508023284.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Priyatham Mettu, M.D has received a total of $65,492 in payments from pharmaceutical and medical device companies, with $23,966 received in 2024. These payments were reported across 52 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($52,750).
As a Medicare-enrolled provider, Mettu has provided services to 9,589 Medicare beneficiaries, totaling 21,505 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Durham, NC
- Active Since 05/20/2008
- Last Updated 07/11/2023
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1508023284
Products in Payments
- Izervay (Drug) $47,700
- ILUVIEN (Drug) $5,377
- Vabysmo (Drug) $2,275
- ForeseeHome (Device) $689.34
- EYLEA (Biological) $219.90
- Syfovre (Drug) $189.85
- VISUDYNE (Drug) $187.05
- EYLEA HD (Biological) $124.14
- LOTEMAX SM (Drug) $105.08
- DEXTENZA (Drug) $93.11
- DEXYCU (Drug) $81.91
- Foresee Home (Device) $51.32
- SUSVIMO (Drug) $40.48
- XIPERE (Drug) $34.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Durham
Julie Woodward, Md, MD
Ophthalmology — Payments: $1.1M
Ophthalmology $1.1M
Terry Kim, M.d, M.D
Ophthalmology — Payments: $955,773
Ophthalmology $955,773
Dr. Lejla Vajzovic, M.d, M.D
Ophthalmology — Payments: $645,013
Ophthalmology $645,013
Glenn Jaffe, M.d, M.D
Ophthalmology — Payments: $323,809
Ophthalmology $323,809
Dr. Robin Vann, M.d, M.D
Ophthalmology — Payments: $281,269
Ophthalmology $281,269
Dr. Victor Perez Quinones, Md, MD
Ophthalmology — Payments: $271,372
Ophthalmology $271,372